Prognosis of Ursodeoxycholic Acid-Treated Patients with Primary Biliary Cirrhosis. Results of a 10-Yr Cohort Study Involving 297 Patients

ter Borg, Pieter C. J.; Schalm, Solko W.; Hansen, Bettina E.; van Buuren, Henk R.
September 2006
American Journal of Gastroenterology;Sep2006, Vol. 101 Issue 9, p2044
Academic Journal
BACKGROUND AND AIMS: The therapeutic potential of ursodeoxycholic acid (UDCA) treatment in primary biliary cirrhosis (PBC) remains controversial. In addition, relatively few data have been reported on the outcome of patients who have been treated long term. The aim of the present study was to document long-term survival of a prospectively followed large cohort of UDCA treated patients in comparison to that predicted by the Mayo model and of a matched control cohort of the Dutch population. METHODS: Two hundred ninety-seven patients were included and followed during a median period of 68 (range 3–126) months until death or the end of the study. RESULTS: Survival free of transplantation (1 yr 99.7%, 5 yr 87%, and 10 yr 71%) was significantly better than predicted by the Mayo model ( p= 0.01). However, for patients with abnormal serum bilirubin and/or albumin concentrations at entry, observed and predicted survival did not significantly differ. Compared with survival for a standardized cohort of the Dutch population, observed survival for the total group was significantly decreased ( p= 0.0003); for noncirrhotic patients and patients with normal entry bilirubin and albumin concentrations survival was comparable. Serum bilirubin and albumin concentrations were the prognostic factors most consistently associated with survival. CONCLUSIONS: A 10-year prognosis for most UDCA-treated patients with PBC, i.e., those with a normal bilirubin and albumin concentration, is comparable to that of a matched general population. Our finding that observed survival was significantly better than predicted by the Mayo model may suggest that this model did not accurately predict prognosis in our cohort. Alternatively, this finding indicates an important therapeutic effect of long-term UDCA treatment in PBC, particularly in patients with noncirrhotic, nonadvanced disease.


Related Articles


    Whether ursodeoxycholic acid (UDCA) slows the progression of primary biliary cirrhosis (PBC) is uncertain according to two meta-analyses. However the randomised trials evaluated have only a median of 24 months follow up. The aim of this study was to evaluate the potential long term effect of...

  • Biochemical response to ursodeoxycholic acid predicts survival in a North American cohort of primary biliary cirrhosis patients. Lammert, Craig; Juran, Brian; Schlicht, Erik; Chan, Landon; Atkinson, Elizabeth; Andrade, Mariza; Lazaridis, Konstantinos // Journal of Gastroenterology;Oct2014, Vol. 49 Issue 10, p1414 

    Background: Biochemical response to ursodeoxycholic acid among patients with primary biliary cirrhosis remains variable, and there is no agreement of an ideal model. Novel assessment of response coupled to histologic progression was recently defined by the Toronto criteria. We retrospectively...

  • Mitochondrial Antibody in Primary Biliary Cirrhosis and Other Diseases. Klatskin, Gerald; Kantor, Fred S. // Annals of Internal Medicine;Oct72, Vol. 77 Issue 4, p533 

    Presents a study that investigated mitochondrial antibody in the serum of patients with primary biliary cirrhosis and other liver diseases. Assessment of the incidence of mitochondrial antibody; Analysis of patients with chronic active hepatitis; Examination of patients with cryptogenic cirrhosis.

  • Incomplete Response to Ursodeoxycholic Acid in Primary Biliary Cirrhosis: Is a Double Dosage Worthwhile? Angulo, Paul; Jorgensen, Roberta A.; Lindor, Keith D. // American Journal of Gastroenterology;Nov2001, Vol. 96 Issue 11, p3152 

    OBJECTIVE: The aim of this study was to assess the safety and efficacy of high-dose ursodeoxycholic acid (UDCA, 28-32 mg/kg/day) in patients with primary biliary cirrhosis (PBC) who had shown an incomplete response to the standard dose (13-15 mg/kg/day). METHODS: A total of 25 patients with PBC...

  • Identification of a Novel 974C→G Nonsense Mutation of the MRP2/ABCC2 Gene in a Patient with Dubin-Johnson Syndrome and Analysis of the Effects of Rifampicin and Ursodeoxycholic Acid on Serum Bilirubin and Bile Acids. Corpechot, Christophe; Chen Ping; Wendum, Dominique; Matsuda, Fumihiko; Barbu, Véronique; Poupon, Raoul // American Journal of Gastroenterology;Oct2006, Vol. 101 Issue 10, p2427 

    Rifampicin (RIF) and ursodeoxycholic acid (UDCA) therapies have beneficial effects in chronic cholestatic diseases. These may result in part from the induction of multidrug-resistance protein 2 (MRP2/ABCC2) expression in the liver and kidney. However, the precise mechanisms by which RIF and UDCA...

  • Retrospective survey on laparoscopic cholecystectomy in the cirrhotic patient. CAPPELLANI, A.; CACOPARDO, B.; ZANGHÌ, A.; CAVALLARO, A.; DI VITA, M.; ALFANO, G.; LO MENZO, E. // European Review for Medical & Pharmacological Sciences;Jul/Aug2008, Vol. 12 Issue 4, p257 

    Cholelitiasis is a common disease in patients with liver cirrhosis, mainly due to intravascular haemolysis and functional alterations of the gallbladder. In Child A and B cirrhotics laparoscopic cholecystectomy (LC) demonstrated the same advantages and safety as in the non cirrhotic patients. On...

  • Treatment of primary biliary cirrhosis. Babbs, C.; Smith, A.; Warnes, T.W. // British Medical Journal (Clinical Research Edition);12/5/1987, Vol. 295 Issue 6611, p1486 

    Focuses on the treatment of biliary cirrhosis. Use of corticosteroids and colchicine; Drug trials to determine potency; Discussions and suggestions for future studies on drugs in the treatment of primary biliary cirrhosis.

  • Four year follow up of fatigue in a geographically defined primary biliary cirrhosis patient cohort. Jones, D. E. J.; Bhala, N.; Burt, J.; Goldblatt, J.; Prince, M.; Newton, J. L. // Gut;Apr2006, Vol. 55 Issue 4, p536 

    Background and aims: Fatigue is the commonest symptom described by patients in most populations with the autoimmune liver disease primary biliary cirrhosis (PBC), and appears to be unrelated to liver disease severity. At present, it is unclear how the fatigue experienced by patients (only...

  • Small Bowel Motility in Primary Biliary Cirrhosis. Madrid, A. M.; Brahm, J.; Antezana, C.; González-Koch, A.; DeOlippi, Cl.; Pimentel, C.; Oksenberg, D.; Defilippi, C. // American Journal of Gastroenterology;Dec1998, Vol. 93 Issue 12, p2436 

    Objective: Previous studies have shown small bowel motor activity abnormalities in patients with liver cirrhosis of different etiologies, but motility has not been studied in patients with primary biliary cirrhosis. Our aim was to investigate proximal small bowel motility in these patients....


Read the Article


Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics